U.S. FDA approves Alembic Pharma’s Clonazepam tablets to treat seizure
Category: #health  By Paroma Bhattacharya  Date: 2019-07-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

U.S. FDA approves Alembic Pharma’s Clonazepam tablets to treat seizure

Alembic Pharmaceuticals, an Indian multinational drug manufacturing company, recently announced that the U.S. Food and Drug administration has granted approval for its orally disintegrating Clonazepam tablets used specifically to treat seizures.

Reportedly, the product is therapeutically equivalent to Klonopin orally disintegrating tablets, a reference listed drug, developed by Hoffmann-La Roche, Inc. Clonazepam is useful as an adjunct or alone in the treatment of Lennox-Gastaut syndrome, myoclonic and akinetic seizures.

Alembic Pharmaceuticals confirmed in a BSE filing that the company’s abbreviated new drug application (ANDA) for Clonazepam orally disintegrating tablets has won approval from the United States Food and Drug Administration. These tablets have strengths ranging from 0.125mg to 2mg. Alembic Pharmaceuticals’ shares had been trading 0.52 percent higher at Rs. 509 on the Bombay Stock Exchange at the time.

According to the data from IQVIA , the estimated market size for clonazepam orally disintegrating tablets USP is around $20 million during the 12 months ending December 2018. Till date, the USFDA has granted the company 98 ANDA approvals out of which 86 are final approval and 12 of them are tentative, sources familiar with the matter informed.

For the uninitiated, a multinational pharmaceutical company situated in Vadodara, Gujrat, Alembic Pharmaceuticals is involved in the manufacturing of pharmaceutical substances, intermediates and pharmaceutical products. Established 1907, the company is leading in the market for anti-infective drugs’ macrolides segment in India.

Alembic Pharmaceutical is also involved in real estate and power generation sectors, with the latter carried out through windmills and cogeneration power plants and is wholly used for captive consumption. It is also engaged in manufacturing and marketing of chemistry and fermentation based Active Pharmaceuticals Ingredients (API), sources mentioned. The company is currently publicly listed for manufacturing and marketing pharmaceutical products around the world.

 

Source Credits- https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-for-seizure-treatment-drug/articleshow/70019754.cms

https://www.thehindubusinessline.com/companies/alembic-pharma-gets-usfda-nod-for-seizure-treatment-drug/article28240654.ece



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Aino Health inks deal with 55BirchStreet to expand in German markets
Aino Health inks deal with 55BirchStreet to expand in German markets
By Paroma Bhattacharya

Reports confirm that Sweden’s Aino Health and 55BirchStreet, a Germany-based digital consulting firm, have recently signed a new partnership agreement. 55BitchStreet will sell implementation services and licenses...

Visa acquires Payworks for an integrated payment acceptance solution
Visa acquires Payworks for an integrated payment acceptance solution
By Paroma Bhattacharya

Visa, the financial services company recently announced acquisition of Payworks, the Munich-based makers of payment gateway software for the POS (point of sale). The company plans to integrate cloud-based solution of P...

MacroGenics, I-Mab team up to develop & market enoblituzumab in China
MacroGenics, I-Mab team up to develop & market enoblituzumab in China
By Paroma Bhattacharya

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announc...